References
- D. A. Fruman, R. E. Meyers, and L. C. Cantley, "Phosphoinositide kinases", Annu. Rev. Biochem., Vol. 67, pp. 481-507, 1998. https://doi.org/10.1146/annurev.biochem.67.1.481
- R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms, and M. D. Waterfield, "Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer", Annu. Rev. Cell Dev. Biol., Vol. 17, pp. 615-675, 2001. https://doi.org/10.1146/annurev.cellbio.17.1.615
- M. Graupera, J. Guillermet-Guibert, L. C. Foukas, L. K. Phng, R. J. Cain, A. Salpekar, W. Pearce, S. Meek, J. Millan, P. R. Cutillas, A. J. H. Smith, A. J. Ridley, C. Ruhrberg, H. Gerhardt, and B. Vanhaesebroeck, "Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature", Nature, Vol. 453, pp. 662-666, 2008. https://doi.org/10.1038/nature06892
- H. Z. Xie, L. L. Li, J. X. Ren, J. Zou, L. Yang, Y. Q. Wei, and S. Y. Yang, "Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors", Bioorg. Med. Chem. Lett., Vol. 19, pp. 1944-1949, 2009. https://doi.org/10.1016/j.bmcl.2009.02.049
- M. O. Taha, N. Atallah, A. G. Al-Bakri, C. Paradis-Bleau, H. Zalloum, K. S. Younis, and R. C. Levesque, "Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening", Bioorg. Med. Chem. Lett., Vol. 16, pp. 1218-1235, 2008. https://doi.org/10.1016/j.bmc.2007.10.076
- H. Y. Wang, Z. X. Cao, L. L. Li, P. D. Jiang, Y. L. Zhao, S. D. Luo, L. Yang, Y. Q. Wei, and S. Y. Yang, "Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors", Bioorg. Med. Chem. Lett., Vol. 18, pp. 4972-4977, 2008. https://doi.org/10.1016/j.bmcl.2008.08.033
- J. Pothier, M. A. Riederer, O. Peter, X. Leroy, A. Valdenaire, C. Gnerre, and H. Fretz, "Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype", Bioorg. Med. Chem. Lett.., Vol. 22, pp. 4660-4667, 2012. https://doi.org/10.1016/j.bmcl.2012.05.087
- S. Y. Yang, "Pharmacophore modeling and applications in drug discovery: challenges and recent advances", Drug Discov. Today, Vol. 15, pp. 444-450, 2010. https://doi.org/10.1016/j.drudis.2010.03.013
- S. L. Dixon, A. M. Smondyrev, E. H. Knoll, S. N. Rao, D. E. Shaw, and R. A. Friesner, "PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening", J. Comput. Aid. Mol. Des., Vol. 20, pp. 647-671, 2006. https://doi.org/10.1007/s10822-006-9087-6
- M. M. Mysinger, M. Carchia, J. J. Irwin, and B. K. Shoichet, "Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking", J. Med. Chem., Vol. 55, pp. 6582-6594, 2012. https://doi.org/10.1021/jm300687e
- J. M. Yang and T. W. Shen, "A pharmacophore-based evolutionary approach for screening selective estrogen receptor modulators", Proteins, Vol. 59, pp. 205-220, 2005. https://doi.org/10.1002/prot.20387
- QikProp, Version 3.2, Schrodinger LLC, New York, USA, 2009.
- SYBYL Software, Version 7.3, Tripos Associates Inc, St. Louis, USA, 2006.